BeOne Medicines vs Teva Pharmaceutical Industries
ONC and TEVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ONC and TEVA compare
BeOne Medicines is the larger company, worth 12 times as much as Teva Pharmaceutical Industries ($615B against $50.4B).
On earnings, Teva Pharmaceutical Industries is cheaper: it trades at 72.1× trailing earnings, against 693× for BeOne Medicines.
BeOne Medicines grew revenue faster over the last twelve months (32.9% versus −15.2% for Teva Pharmaceutical Industries).
BeOne Medicines keeps more of each dollar of sales as profit, with a net margin of 13.9% compared with 5.0% at Teva Pharmaceutical Industries.
BeOne Medicines scores higher on the StockData Score (14 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ONC | TEVA |
|---|---|---|
| Size and price | ||
| Market cap | $615B | $50.4B |
| Share price | $415.96 | $43.24 |
| Change, 1 year | 21.0% | 78.2% |
| Change, 5 years | 14.1% | 387% |
| Beta (5Y) | 1.04 | 0.98 |
| Employees | 12K | 34K |
| StockData Score | ||
| Total score | 14 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 4 | 4 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 693× | 72.1× (better) |
| P/S | 93.1× | 3.6× (better) |
| P/B | 106× | 6.5× (better) |
| EV/EBITDA | 450× | 19.8× (better) |
| P/FCF | 424× | 37.4× (better) |
| FCF yield | 0.24% | 2.7% (better) |
| Fair value | $20.30 | $19.78 |
| Margin of safety | −1949% | −119% (better) |
| Growth | ||
| Revenue growth (TTM) | 32.9% (better) | −15.2% |
| Revenue growth, 5Y average | 76.8% (better) | 0.71% |
| Net income growth (TTM) | 1236% | – |
| EPS growth (TTM) | 1900% | – |
| Profitability | ||
| Gross margin | 89.4% (better) | 64.4% |
| Operating margin | 17.8% (better) | 11.4% |
| Net margin | 13.9% (better) | 5.0% |
| FCF margin | 21.9% (better) | 9.6% |
| Return on equity | 18.4% (better) | 9.7% |
| Return on invested capital | 88.9% (better) | 23.0% |
| Financial health | ||
| Debt / equity | 0.21 (better) | 0.58 |
| Net debt / EBITDA | −3.37 | 0.33 (better) |
| Interest coverage | 8.3× | – |
| Current ratio | 3.55 (better) | 0.88 |
| Altman Z-score | 91.66 (better) | 0.88 |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 2.4% | – |
| Held by insiders | 13.9% | 0.43% |
| Insider net buying, 12 months | −$384M | −$108M (better) |
| Short interest, % of float | – | 2.4% |
Go deeper
- ONC stock overview
- ONC income statement
- ONC valuation and score
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.